Moreover, elevated levels of miR-126 increased Aβ42-induced toxicity and interfered with the neuroprotective effects of IGF-1 by inhibiting PI3K and ERK pathways (41), suggesting miR-126 may be a potential molecular target for AD treatment. This evidence concerns the gene MAPK1 and Alzheimer disease.